<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8(21)</volume><submitter>Li Y</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>To evaluate the association between use of proton pump inhibitor (PPI) and the risk of hospital-acquired acute kidney injury (HA-AKI) in hospitalized children.&lt;h4>Methods&lt;/h4>We conducted a multicenter retrospective cohort study in hospitalized children aged 1 month to 18 years from 25 tertiary hospitals across China from 2013 to 2015. Patient-level data were obtained from the electronic hospitalization databases. AKI was defined and staged using the serum creatinine (SCr) data according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria.&lt;h4>Results&lt;/h4>Among 42,232 children analyzed, 11,496 (27.2%) used PPI, 1,760 (4.2%) used histamine 2 receptor antagonist (H2RA), and 3,514 (8.3%) had HA-AKI during hospitalization. Over 85% of PPIs were prescribed for prophylaxis of gastro-duodenal lesions in children. The use of PPI was associated with a significantly increased risk of HA-AKI compared with both non-users [odds ratio (OR), 1.37; 95% confidence interval (CI), 1.23-1.53)] and H2RA users (OR, 1.24; 95% CI, 1.01-1.52). The associations were consistent across children of different age range, gender, subtypes of PPIs and methods of administration. A larger effect was observed in children with chronic kidney disease (OR, 3.37; 95% CI, 2.46-4.62) and those needed intensive care (OR, 1.54; 95% CI, 1.33-1.78). The risk of HA-AKI was increased even within the recommended dosage range of PPI.&lt;h4>Conclusions&lt;/h4>PPIs were widely used and associated with an increased risk of HA-AKI in hospitalized children in China.</pubmed_abstract><journal>Annals of translational medicine</journal><pagination>1438</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7723554</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Proton pump inhibitors and the risk of hospital-acquired acute kidney injury in children.</pubmed_title><pmcid>PMC7723554</pmcid><pubmed_authors>Xiong M</pubmed_authors><pubmed_authors>Liu BC</pubmed_authors><pubmed_authors>Feng JH</pubmed_authors><pubmed_authors>Wang L</pubmed_authors><pubmed_authors>Mao J</pubmed_authors><pubmed_authors>Liu X</pubmed_authors><pubmed_authors>Wang M</pubmed_authors><pubmed_authors>Ge S</pubmed_authors><pubmed_authors>Xia H</pubmed_authors><pubmed_authors>Liu Z</pubmed_authors><pubmed_authors>Hou FF</pubmed_authors><pubmed_authors>Liu HP</pubmed_authors><pubmed_authors>Zhang A</pubmed_authors><pubmed_authors>Tang Y</pubmed_authors><pubmed_authors>Nie S</pubmed_authors><pubmed_authors>Pi M</pubmed_authors><pubmed_authors>Teng S</pubmed_authors><pubmed_authors>Chen J</pubmed_authors><pubmed_authors>Yang M</pubmed_authors><pubmed_authors>Feng Y</pubmed_authors><pubmed_authors>Zha Y</pubmed_authors><pubmed_authors>Zhou W</pubmed_authors><pubmed_authors>Li Q</pubmed_authors><pubmed_authors>Xu H</pubmed_authors><pubmed_authors>Chen C</pubmed_authors><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>He Y</pubmed_authors><pubmed_authors>Tao Y</pubmed_authors><pubmed_authors>He W</pubmed_authors><pubmed_authors>Liu D</pubmed_authors><pubmed_authors>Xu X</pubmed_authors><pubmed_authors>Feng S</pubmed_authors><pubmed_authors>Hao C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Proton pump inhibitors and the risk of hospital-acquired acute kidney injury in children.</name><description>&lt;h4>Background&lt;/h4>To evaluate the association between use of proton pump inhibitor (PPI) and the risk of hospital-acquired acute kidney injury (HA-AKI) in hospitalized children.&lt;h4>Methods&lt;/h4>We conducted a multicenter retrospective cohort study in hospitalized children aged 1 month to 18 years from 25 tertiary hospitals across China from 2013 to 2015. Patient-level data were obtained from the electronic hospitalization databases. AKI was defined and staged using the serum creatinine (SCr) data according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria.&lt;h4>Results&lt;/h4>Among 42,232 children analyzed, 11,496 (27.2%) used PPI, 1,760 (4.2%) used histamine 2 receptor antagonist (H2RA), and 3,514 (8.3%) had HA-AKI during hospitalization. Over 85% of PPIs were prescribed for prophylaxis of gastro-duodenal lesions in children. The use of PPI was associated with a significantly increased risk of HA-AKI compared with both non-users [odds ratio (OR), 1.37; 95% confidence interval (CI), 1.23-1.53)] and H2RA users (OR, 1.24; 95% CI, 1.01-1.52). The associations were consistent across children of different age range, gender, subtypes of PPIs and methods of administration. A larger effect was observed in children with chronic kidney disease (OR, 3.37; 95% CI, 2.46-4.62) and those needed intensive care (OR, 1.54; 95% CI, 1.33-1.78). The risk of HA-AKI was increased even within the recommended dosage range of PPI.&lt;h4>Conclusions&lt;/h4>PPIs were widely used and associated with an increased risk of HA-AKI in hospitalized children in China.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Nov</publication><modification>2025-04-22T01:17:47.326Z</modification><creation>2025-04-05T19:55:50.019Z</creation></dates><accession>S-EPMC7723554</accession><cross_references><pubmed>33313183</pubmed><doi>10.21037/atm-20-2284</doi></cross_references></HashMap>